Búsqueda | Biblioteca Virtual en Salud

1.

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Koschmieder, Steffen; Isfort, Susanne; Schulte, Clemens; Jacobasch, Lutz; Geer, Thomas; Reiser, Marcel; Koenigsmann, Michael; Heinrich, Bernhard; Wehmeyer, Jürgen; von der Heyde, Eyck; Tesch, Hans; Gröschl, Benedikt; Bachhuber, Petra; Großer, Susanne; Pahl, Heike L.

Ann Hematol ; 102(12): 3383-3399, 2023 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-37792065

2.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Jutzi, Jonas Samuel; Basu, Titiksha; Pellmann, Maximilian; Kaiser, Sandra; Steinemann, Doris; Sanders, Mathijs A; Hinai, Adil S A; Zeilemaker, Annelieke; Bojtine Kovacs, Sarolta; Koellerer, Christoph; Ostendorp, Jenny; Aumann, Konrad; Wang, Wei; Raffoux, Emmanuel; Cassinat, Bruno; Bullinger, Lars; Schlegelberger, Brigitte; Valk, Peter J M; Pahl, Heike Luise.

Blood ; 133(16): 1766-1777, 2019 04 18.

Artículo en Inglés | MEDLINE | ID: mdl-30755419

3.

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.

Peeken, Jan C; Jutzi, Jonas S; Wehrle, Julius; Koellerer, Christoph; Staehle, Hans F; Becker, Heiko; Schoenwandt, Elias; Seeger, Thalia S; Schanne, Daniel H; Gothwal, Monika; Ott, Christopher J; Gründer, Albert; Pahl, Heike L.

Blood ; 131(18): 2065-2073, 2018 05 03.

Artículo en Inglés | MEDLINE | ID: mdl-29519804

4.

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.

Stosch, Juliane M; Heumüller, Anezka; Niemöller, Christoph; Bleul, Sabine; Rothenberg-Thurley, Maja; Riba, Julian; Renz, Nathalie; Szarc Vel Szic, Katarzyna; Pfeifer, Dietmar; Follo, Marie; Pahl, Heike L; Zimmermann, Stefan; Duyster, Justus; Wehrle, Julius; Lübbert, Michael; Metzeler, Klaus H; Claus, Rainer; Becker, Heiko.

Br J Haematol ; 182(6): 830-842, 2018 09.

Artículo en Inglés | MEDLINE | ID: mdl-29974943

5.

Sentinel mutations: the roses in the vineyard.

Pahl, Heike L.

Blood ; 138(21): 2019-2020, 2021 11 25.

Artículo en Inglés | MEDLINE | ID: mdl-34821937

6.

Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.

Limberger, Kathrin A; Bogatyreva, Lioudmila; Todorova, Rumyana; Herde, Bettina; Hauschke, Dieter; Pahl, Heike L; Werner, Martin; Aumann, Konrad.

Histochem Cell Biol ; 147(1): 75-82, 2017 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-27544663

7.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer, Holly L; Kosiorek, Heidi; Dueck, Amylou C; Scherber, Robyn; Slot, Stefanie; Zweegman, Sonja; Te Boekhorst, Peter Aw; Senyak, Zhenya; Schouten, Harry C; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Pahl, Heike L; Griesshammer, Martin; Stegelmann, Frank; Döhner, Konstanze; Lehmann, Thomas; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean-Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean-Yves; Harrison, Claire N; Radia, Deepti; Muxi, Pablo; Maldonado, Norman; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M; Paoli, Chiara; Passamonti, Francesco; Andreasson, Bjorn; Ferrari, Maria L; Rambaldi, Alessandro; Samuelsson, Jan; Cannon, Keith; Birgegard, Gunnar; Xiao, Zhijian; Xu, Zefeng; Zhang, Yue; Sun, Xiujuan; Xu, Junqing; Kiladjian, Jean-Jacques; Zhang, Peihong.

Haematologica ; 102(1): 85-93, 2017 01.

Artículo en Inglés | MEDLINE | ID: mdl-27540137

8.

Many roads lead to MPN.

Pahl, Heike L.

Blood ; 123(14): 2133-4, 2014 Apr 03.

Artículo en Inglés | MEDLINE | ID: mdl-24700715

9.

A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy.

Gothwal, Monika; Wehrle, Julius; Aumann, Konrad; Zimmermann, Vanessa; Gründer, Albert; Pahl, Heike L.

Haematologica ; 101(9): 1054-64, 2016 09.

Artículo en Inglés | MEDLINE | ID: mdl-27479815

10.

Concomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia.

Clemens Böckelmann, Lukas; Basu, Titiksha; Gründer, Albert; Wang, Wei; Breucker, Jan; Kaiser, Sandra; Pichler, Andrea; Pahl, Heike Luise.

Haematologica ; 106(4): 1158-1162, 2021 04 01.

Artículo en Inglés | MEDLINE | ID: mdl-32554556

11.

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Aumann, Konrad; Frey, Anna-Verena; May, Annette M; Hauschke, Dieter; Kreutz, Clemens; Marx, Jan P; Timmer, Jens; Werner, Martin; Pahl, Heike L.

Blood ; 122(1): 93-9, 2013 Jul 04.

Artículo en Inglés | MEDLINE | ID: mdl-23670178

12.

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.

Jutzi, Jonas S; Pahl, Heike L.

Mediators Inflamm ; 2015: 101987, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-26543325

13.

A JAK-in-the-cell cycle.

Pahl, Heike L.

Blood ; 119(5): 1096-7, 2012 Feb 02.

Artículo en Inglés | MEDLINE | ID: mdl-22308276

14.

Ponatinib: a third-generation inhibitor for the treatment of CML.

Wehrle, Julius; Pahl, Heike L; von Bubnoff, Nikolas.

Recent Results Cancer Res ; 201: 99-107, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-24756787

15.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Fleischman, Angela G; Aichberger, Karl J; Luty, Samuel B; Bumm, Thomas G; Petersen, Curtis L; Doratotaj, Shirin; Vasudevan, Kavin B; LaTocha, Dorian H; Yang, Fei; Press, Richard D; Loriaux, Marc M; Pahl, Heike L; Silver, Richard T; Agarwal, Anupriya; O'Hare, Thomas; Druker, Brian J; Bagby, Grover C; Deininger, Michael W.

Blood ; 118(24): 6392-8, 2011 Dec 08.

Artículo en Inglés | MEDLINE | ID: mdl-21860020

16.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

Wehrle, Julius; Seeger, Thalia S; Schwemmers, Sven; Pfeifer, Dietmar; Bulashevska, Alla; Pahl, Heike L.

Haematologica ; 98(7): 1073-80, 2013 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-23445878

17.

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2^V617F mutated cells.

Staehle, Anne Marie; Peeken, Jan Caspar; Vladimirov, Georg; Hoeness, Mirjam Elisabeth; Bojtine Kovacs, Sarolta; Karantzelis, Nikolaos; Gruender, Albert; Koellerer, Christoph; Jutzi, Jonas Samuel; Pahl, Heike Luise; Staehle, Hans Felix.

Leukemia ; 37(4): 919-923, 2023 04.

Artículo en Inglés | MEDLINE | ID: mdl-36709354

18.

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

Zhang, Yu Wei; Velasco-Hernandez, Talia; Mess, Julian; Lalioti, Maria-Eleni; Romero-Mulero, Mari Carmen; Obier, Nadine; Karantzelis, Nikolaos; Rettkowski, Jasmin; Schönberger, Katharina; Karabacz, Noémie; Jäcklein, Karin; Morishima, Tatsuya; Trincado, Juan Luis; Romecin, Paola; Martinez, Alba; Takizawa, Hitoshi; Shoumariyeh, Khalid; Renders, Simon; Zeiser, Robert; Pahl, Heike L; Béliveau, François; Hébert, Josée; Lehnertz, Bernhard; Sauvageau, Guy; Menendez, Pablo; Cabezas-Wallscheid, Nina.

Blood Adv ; 7(24): 7525-7538, 2023 12 26.

Artículo en Inglés | MEDLINE | ID: mdl-37639313

19.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Wang, Wei; Schwemmers, Sven; Hexner, Elizabeth O; Pahl, Heike L.

Blood ; 116(2): 254-66, 2010 Jul 15.

Artículo en Inglés | MEDLINE | ID: mdl-20339092

20.

New C3H Kit^N824K/WT cancer mouse model develops late-onset malignant mammary tumors with high penetrance.

Klein-Rodewald, Tanja; Micklich, Kateryna; Sanz-Moreno, Adrián; Tost, Monica; Calzada-Wack, Julia; Adler, Thure; Klaften, Matthias; Sabrautzki, Sibylle; Aigner, Bernhard; Kraiger, Markus; Gailus-Durner, Valerie; Fuchs, Helmut; Gründer, Albert; Pahl, Heike; Wolf, Eckhard; Hrabe de Angelis, Martin; Rathkolb, Birgit.

Sci Rep ; 12(1): 19793, 2022 11 17.

Artículo en Inglés | MEDLINE | ID: mdl-36396684

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.

Sentinel mutations: the roses in the vineyard.

Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Many roads lead to MPN.

A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy.

Concomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia.

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.

A JAK-in-the-cell cycle.

Ponatinib: a third-generation inhibitor for the treatment of CML.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2^V617F mutated cells.

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

New C3H Kit^N824K/WT cancer mouse model develops late-onset malignant mammary tumors with high penetrance.